Biosolvix
Biosolvix is a Seoul-based organoid CRO founded in 2023 that provides hiPSC-derived organoid and organ-on-a-chip drug efficacy and toxicity testing services for pharmaceutical, biotech, hospital, and academic clients, leveraging its Avatoid® platform.
- Company typePrivate
- Founded2023
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Biosolvix does
Biosolvix is a South Korea-based contract research organization (CRO) founded in May 2023 that provides organoid-based drug efficacy and toxicity evaluation services as alternatives to animal testing. The company operates an hiPSC (human induced pluripotent stem cell)-derived organoid platform branded as Avatoid®, spanning cardiac, neural, liver, and cancer tissue models, plus an SFI-Chip organ-on-a-chip system for simultaneous multi-organoid screening. Its service portfolio includes Safety & Efficacy Evaluation, Cancer Organoid services for personalized drug screening, Drug Screening & Toxicity Studies (Patch Clamp, MEA, Cardio ECR), and Organ-on-a-Chip testing, delivered on a consignment basis with quotation-based pricing.
The company generates revenue through three primary streams: CRO testing consignment services (beta launched August 2023), technology transfer and licensing of its organoid manufacturing patents and SFI-Chip, and — newly entering in December 2024 — cosmetics manufacturing using stem-cell-based ingredients under a Korean cosmetic manufacturing license. Its go-to-market is direct B2B enterprise sales targeting pharmaceutical and biotech companies (SMEs and large pharma), supplemented by partnerships with hospitals (Samsung Seoul Hospital, Seoul St. Mary's Hospital), academic institutions (Catholic, Central, Ajou, Korea Universities), and CROs (Dt&CRO), and event-driven lead generation at conferences such as CPHI North America 2024 and NextRise 2025.
Biosolvix positions itself as Korea's first specialized Organoid CRO. The company holds multiple granted Korean patents (cardiac, neural, liver organoids; microfluidic chip; ANN arrhythmia screening), maintains an AI-based cardiotoxicity prediction platform (AUC 0.94) developed with several Korean universities, and has secured government support through TIPS, Scale-up TIPS (~1.1 billion KRW), the Innovation Premier 1000 program, and a five-year regenerative medicine technology development project (~2.3 billion KRW). It is preparing a Series A round and targets capturing 1% of the Korean non-clinical CRO market (~50 billion KRW) within three years against a 22.1% CAGR global organoid market backdrop.
Biosolvix firmographics
Firmographics- Name
- Biosolvix
- Legal name
- Biosolvix Co., Ltd. (바이오솔빅스)
- Website
- https://biosolvix.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Biosolvix is a Seoul-based organoid CRO founded in 2023 that provides hiPSC-derived organoid and organ-on-a-chip drug efficacy and toxicity testing services for pharmaceutical, biotech, hospital, and academic clients, leveraging its Avatoid® platform.
- Ownership category
- akta.pro rank
Where Biosolvix is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices3 records
Markets served
Biosolvix business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Organoid CRO Services (Testing Consignment): BioSolvix operates as Korea's first specialized Organoid CRO, providing contract research services for drug efficacy and toxicity evaluation using human-derived organoids. Services are offered through a consignment testing process where pharmaceutical and biotech companies submit requests for quotation (RFQ). Revenue is generated through service fees for specific testing contracts. The beta service was opened in August 2023 with full commercial operations ongoing.
- Technology Transfer and Licensing: BioSolvix generates revenue through transfer agreements for its proprietary technologies, including AI toxicity technology transfer (August 2023), SFI-Chip (Organ on a chip) technology transfer (August 2023), and organoid technology patents. The company also licenses its organoid manufacturing methods and protocols to partners.
- Cosmetics Manufacturing: BioSolvix obtained a cosmetic manufacturing license in December 2024, enabling the company to develop and manufacture stem cell-based cosmetic products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Beta testing service for toxicity and efficacy evaluation |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Biosolvix product offering
Product offeringCore offering
Biosolvix is a contract research organization providing drug efficacy and toxicity evaluation services using human induced pluripotent stem cell (hiPSC)-derived organoids and patient-derived cancer organoids as alternatives to animal testing. Its Avatoid® platform encompasses cardiac, neural, liver, and cancer organoid products, complemented by the proprietary SFI-Chip organ-on-a-chip and an AI-based cardiotoxicity prediction engine. Services are delivered to pharmaceutical, biotech, academic, and hospital clients on a consignment testing basis.
Product overview
BioSolvix is a specialized organoid Contract Research Organization (CRO) offering a comprehensive platform of stem cell and organoid-based services. The company's flagship Avatoid® technology platform encompasses hiPSC-derived organoids (cardiac, neural, liver) and cancer organoids for drug efficacy and toxicity testing. Core services include Safety & Efficacy Evaluation using tissue-mimicking analogs, Cancer Organoid services for personalized medicine, Drug Screening & Toxicity Studies using high-purity cardiomyocytes, and the SFI-Chip Organ on a Chip technology for multi-organoid screening. The company operates as Korea's first specialized Organoid CRO, providing animal-free testing alternatives for preclinical drug development.
Differentiator
Problem solved
Functional benefit
Products and services
- hiPSC-derived Cardiac Organoid (Cardiac Avatoid®) Service Safety and efficacy evaluation service using human induced pluripotent stem cell-derived cardiac organoids (tissue-mimicking analogs) for cardiotoxicity and drug efficacy assessment. Utilizes ventricular-like hiPSC-CMs with electrophysiological properties similar to native heart tissue for pharmaceutical and biotech clients.
- hiPSC-derived Neural Organoid (Neural Avatoid®) Service Safety and efficacy evaluation service using human induced pluripotent stem cell-derived neural organoids for neurotoxicity assessment and drug efficacy testing, targeting pharmaceutical and biotech clients developing CNS-active compounds.
- hiPSC-derived Liver Organoid (Liver Avatoid®) Service Safety and efficacy evaluation service using human induced pluripotent stem cell-derived liver organoids for hepatotoxicity assessment and drug metabolism analysis, applied to preclinical drug development.
- Cancer Organoid (Cancer Avatoid®) Service Cancer efficacy evaluation service using cancer cell lines and patient-derived tissue-mimicking analogs for personalized drug screening and efficacy assessment. Targets pharmaceutical companies, hospitals, and research institutions pursuing precision oncology.
- Drug Screening & Toxicity Study Service Comprehensive drug screening and toxicity evaluation services using high-purity hiPSC-derived cardiomyocytes, including cardiac drug screening via Patch Clamp, MEA (Multielectrode Array), and Cardio ECR analysis. Serves pharmaceutical and biotech clients in preclinical drug safety assessment.
- SFI-Chip (Organ on a Chip) Service Spheroid-based Flow Integration 3D cell culture chip technology enabling same-size multi-cell-type spheroid/organoid formation, metabolism analysis, and simultaneous multi-drug screening across various organoid types. Supports high-throughput drug screening for pharmaceutical clients.
- Stem Cell-based Cosmetics Manufacturing
Quantifiable outcome
- AI-based cardiotoxicity prediction with AUC 0.94 accuracy for cardiac adverse reaction risk assessment
- +3 more outcomes
Companies that use Biosolvix
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
Biosolvix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Biosolvix partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered major and core.
- SaluscaremajorStrategic MOU signed in June 2025 with Saluscare, a customized healthcare service company. The partnership aims to establish a digital healthcare and stem cell-based preventive medicine platform through technology exchange and joint marketing. Focuses on developing personalized health management services and precision medicine solutions.
- Genesis Bio Research InstitutemajorMOU signed in June 2025 for joint R&D and commercialization in the anti-aging field. BioSolvix conducts cardiac toxicity evaluation (using hiPSC-CMs for mitochondrial metabolism and electrophysiological stability), neural toxicity evaluation (synapse function and structural growth analysis), and quantitative analysis (calcium imaging, neurite growth analysis) for Genesis's health functional food ingredients.
- Seoul St. Mary's Hospital, Hippocrates, Predictive, Korean Society of Geriatric Musculoskeletal MedicinemajorMOU signed in August 2024 with four healthcare organizations including Seoul St. Mary's Hospital, Hippocrates, Predictive, and the Korean Society of Geriatric Musculoskeletal Medicine. The partnership aims to develop treatments for degenerative diseases and intractable diseases using organoid technology.
- DongKook Pharmaceutical and MediramamajorMOU signed in March 2024 with DongKook Pharmaceutical and Medirama for efficacy validation of candidate substances using organoid technology. Enables drug development collaboration leveraging organoid-based evaluation platforms.
- Samsung Seoul HospitalcoreSigned joint research agreement in January 2024 for colorectal and lung cancer organoid development. Additionally signed an MOU in October 2023 with Samsung Medical Center for cancer organoid research collaboration. The partnership enables development of patient-derived cancer organoid models for drug screening.
- Catholic UniversitymajorMOU with Catholic University Surgery Department (November 2023) for organoid technology development. Also entered a commissioned research agreement (August 2023). The partnership focuses on developing various organoid types for drug evaluation.
- Central UniversitymajorCommissioned research contract signed in August 2023 with Central University for outsourced research activities. Also collaborated on World Day for Laboratory Animals campaigns in 2024 and 2025. The university provides research support and academic collaboration for organoid technology development.
Scale indicators6 records
Recent moves4 records
Biosolvix competitors and assessment
Company assessmentMarket position
Key risks6 records
Key highlights7 records
Customer concentration
Biosolvix social profiles
Digital presenceBiosolvix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biosolvix leadership team
Management profileNumber of profiles
Profiles6 records
Biosolvix funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biosolvix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biosolvix
What does Biosolvix do?
Biosolvix is a contract research organization providing drug efficacy and toxicity evaluation services using human induced pluripotent stem cell (hiPSC)-derived organoids and patient-derived cancer organoids as alternatives to animal testing. Its Avatoid® platform encompasses cardiac, neural, liver, and cancer organoid products, complemented by the proprietary SFI-Chip organ-on-a-chip and an AI-based cardiotoxicity prediction engine. Services are delivered to pharmaceutical, biotech, academic, and hospital clients on a consignment testing basis.
Is Biosolvix a public or private company?
Biosolvix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Biosolvix founded?
Biosolvix was founded in 2023. It employs 11 to 50 people.
Where is Biosolvix based?
Biosolvix is headquartered in Seoul, South Korea, in the Asia region.
How does Biosolvix make money?
Three revenue lines are on record. Organoid CRO Services (Testing Consignment) is the primary driver. The others are technology Transfer and Licensing and cosmetics Manufacturing.
Does Biosolvix have an API?
No public API is recorded for Biosolvix.